


CLAIMS

1. Use of at least one of



,


, and


,

Compound 1 Compound 2 Compound 3

or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof,

in combination with at least one second therapeutic agent or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in the manufacture of a medicament for treating a cell proliferative disorder.

2. The use of claim 1, wherein the at least one second therapeutic agent comprises an immunotherapy.

3. The use of claim 2, wherein the immunotherapy is a checkpoint inhibitor.

4 The use of claim 3, wherein the checkpoint inhibitor is an antibody selected from an anti-CTLA4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, anti-A2AR antibody, anti-B7-H3 antibody, anti-B7-H4 antibody, anti-BTLA antibody, anti-IDO antibody, anti-KIR antibody, anti-LAG3 antibody, anti-TIM3 antibody, and anti-VISTA (V-domain Ig suppressor of T cell activation) antibody.

5. The use of claim 4, wherein the antibody is ipilimumab, tremelimumab, AGEN-1884, pembrolizumab, nivolumab, pidlizumab, cemiplimab, REGN2810, AMP-224, MEDI0680, PDR001, JS001 (toripalimab), BGB-A317 (tislelizumab), CT-011, atezolizumab, avelumab or durvalumab.

6. The use of claim 3, wherein the checkpoint inhibitor is an agent selected from Table 3.

7. The use of claim 1, wherein the at least one second therapeutic agent comprises an androgen receptor antagonist, wherein the androgen receptor antagonist is selected from Table 1.

8. The use of claim 1, wherein the at least one second therapeutic agent comprises an estrogen receptor antagonist, wherein the estrogen receptor antagonist is selected from Table 2.

9. The use of claim 1, wherein the at least one second therapeutic agent comprises a cyclin-dependent kinase inhibitor, wherein the cyclin-dependent kinase inhibitor is selected from Table 4.

10. The use of claim 1, wherein the at least one second therapeutic agent is a poly-ADP ribose polymerase inhibitor.

11. The use of claim 10, wherein the poly-ADP ribose polymerase inhibitor is olaparib, talazoparib, rucaparib or pamiparib (BGB-290).

12. The use of claim 1, wherein the at least one second therapeutic agent comprises a mitotic inhibitor.

13. The use of claim 12, wherein the mitotic inhibitor is paclitaxel or nab-taxane.

14. The use of claim 1, wherein the medicament is to be administered with a further therapeutic agent.

15. The use of claim 14, wherein the further therapeutic agent is at least one second therapeutic agent.

16. The use of claim 14, wherein the further therapeutic agent is a chemotherapeutic agent.

17. The use of claim 14, wherein the at least one second therapeutic agent is an estrogen receptor antagonist.

18. The use of claim 14, wherein the at least one second therapeutic agent is an androgen receptor antagonist.

19. The use of claim 14, wherein the at least one second therapeutic agent is a mitotic inhibitor.

20. The use of claim 19, wherein the mitotic inhibitor is paclitaxel or nab-taxane.

21. The use of claim 20, wherein the further therapeutic agent is an immunotherapeutic agent.


22. The use of claim 21, wherein the immunotherapeutic agent is an anti-PD-1 or anti-PD-L1 antibody.


23. The use of claim 22, wherein the immunotherapeutic agent is selected from pembrolizumab, tislelizumab or atezolizumab.


24. The use of claim 1, wherein the cell proliferative disorder is breast cancer.

25. The use of claim 1, wherein the cell proliferative disorder is a cancer.

26. A compound of



,



, and



,


Compound 1 Compound 2 Compound 3

or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, for use in combination with at least one second therapeutic agent or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in treating or preventing a cell proliferative disorder.

27. A pharmaceutical composition comprising a therapeutically effective amount of at least one of



,


, and


,

Compound 1 Compound 2 Compound 3

or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and at least one second therapeutic agent or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.